Aluminium Nanoparticles as Efficient Adjuvants Compared to Their Microparticle Counterparts: Current Progress and Perspectives

Aluminium (Al) compounds are used as adjuvants in human and veterinary prophylactic vaccines due to their improved tolerability compared to other adjuvants. These Al-based adjuvants form microparticles (MPs) of heterogeneous sizes ranging from ~0.5 to 10 µm and generally induce type 2 (Th2)-biased i...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-04, Vol.23 (9), p.4707
Main Authors: Nazarizadeh, Ali, Staudacher, Alexander H, Wittwer, Nicole L, Turnbull, Tyron, Brown, Michael P, Kempson, Ivan
Format: Article
Language:English
Subjects:
adjuvant
Adjuvanticity
Adjuvants
Adjuvants, Immunologic - pharmacology
Adjuvants, Pharmaceutic
Adsorption
aluminium
Aluminum
Antigens
Cancer
Cancer immunotherapy
Cancer vaccines
Cytotoxicity
FDA approval
HIV
Human immunodeficiency virus
Humans
Immune system
Immunotherapy
Infectious diseases
Lymphocytes
Lymphocytes T
Nanoparticles
nanotechnology
Oncolysis
Pathogens
Polyethylene glycol
Review
Tuberculosis
vaccine
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aluminium (Al) compounds are used as adjuvants in human and veterinary prophylactic vaccines due to their improved tolerability compared to other adjuvants. These Al-based adjuvants form microparticles (MPs) of heterogeneous sizes ranging from ~0.5 to 10 µm and generally induce type 2 (Th2)-biased immune responses. However, recent literature indicates that moving from micron dimension particles toward the nanoscale can modify the adjuvanticity of Al towards type 1 (Th1) responses, which can potentially be exploited for the development of vaccines for which Th1 immunity is crucial. Specifically, in the context of cancer treatments, Al nanoparticles (Al-NPs) can induce a more balanced (Th1/Th2), robust, and durable immune response associated with an increased number of cytotoxic T cells compared to Al-MPs, which are more favourable for stimulating an oncolytic response. In this review, we compare the adjuvant properties of Al-NPs to those of Al-MPs in the context of infectious disease vaccines and cancer immunotherapy and provide perspectives for future research.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23094707